AI · SaaS
Boca Raton, Florida Friday Oct 9, 2026 @ 4:00 AM Eastern —
Wolfson Group, a Scotland-based international consumer wellness company, today announced that three brands from its portfolio, PhenQ, TestoPrime, and YourBiology, are coming soon to OneLavi.com, marking another step in the company's strategy to expand U.S. distribution beyond Amazon.
The upcoming OneLavi availability will provide another online destination for U.S. consumers to discover and purchase Wolfson Group brands while supporting the company's broader effort to build a diversified retail and e-commerce presence in the United States.
"Expanding onto OneLavi is another important step in making our brands more accessible to consumers across the U.S.," said the founder and CEO of Wolfson Group. "Amazon has provided us with a strong foundation in the market, and we're now building on that presence by developing additional channels for our portfolio."
The three brands coming to OneLavi represent distinct areas of the consumer wellness market. PhenQ focuses on weight management, TestoPrime serves the men's wellbeing category, and YourBiology focuses on women's gut health and everyday wellness.
The expansion follows a series of U.S. initiatives by Wolfson Group as the Scotland-based company works to broaden its American presence. In September, Wolfson Group participated in the ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida, where the company introduced its multi-category portfolio during scheduled retail meetings.
Wolfson Group has also been examining how consumer wellness interests increasingly extend across multiple categories, including weight management, cognitive wellness, gut health, men's and women's wellbeing and healthy ageing. The company believes its diversified portfolio provides opportunities to serve consumers with different wellness priorities throughout various stages of life.
Adding OneLavi to Wolfson Group's U.S. distribution strategy reflects the company's approach of building multiple paths to the consumer rather than relying on a single marketplace or retail channel.
"Our U.S. strategy is about creating a broader and more sustainable distribution footprint over time," the founder said. "Adding new online retail relationships complements what we've already built and gives us another foundation as we continue exploring opportunities across both e-commerce and brick-and-mortar retail."
Wolfson Group said it will continue pursuing additional U.S. distribution opportunities while investing in consumer education, science-led brand development and long-term growth across its portfolio.
PhenQ, TestoPrime, NooCube and YourBiology are already available to U.S. consumers through Amazon. Their upcoming availability on OneLavi will add another online retail channel as Wolfson Group continues building a broader U.S. distribution footprint.
About Wolfson Group
Wolfson Group is an international consumer wellness company focused on building science-led brands that help people live healthier lives. Its portfolio spans weight management, cognitive health, gut health, men's wellness, beauty and healthy ageing, serving millions of consumers worldwide through direct-to-consumer, marketplace and retail channels.
Wolfson Group's portfolio includes the established wellness brands PhenQ, TestoPrime, NooCube and YourBiology, spanning categories such as weight management, cognitive wellness, gut health and men's wellbeing. The brands are currently available to U.S. consumers through Amazon while the company pursues broader retail opportunities nationwide.
Oct 9 · 08:00·Newsworthy.ai
AI · SaaS
New agreement incorporates advanced generative AI, security, and infrastructure capabilities to drive technological transformation SUNNYVALE, Calif. and MADRID, Oct. 9, 2026 -- CaixaBank today announced an expanded strategic agreement with Google Cloud, strengthening its...
Oct 9 · 08:00·PR Newswire
SaaS
Chengdu, China--(October 9, 2026) - The 12th Chengdu International Urban Modern Agriculture Expo was held from September 28 to 30 in Chengdu, Sichuan Province, China. Covering 33,000 square meters, the expo attracted 816 companies from 12 countries and showcased more than 4,100 agricultural products. Focusing on modern agricultural technology, specialty agricultural products and international trade cooperation, the event provided a platform for domestic and international...
Oct 9 · 07:49·Newsfile
SaaS
BEIJING, Oct. 9, 2026 -- In early September 2026, Egyptian young man named Abbas launched an account on a Chinese social media platform. In his profile, he proudly noted that he had been featured three times in the People's Daily. His first post was the newspaper's latest...
Oct 9 · 07:40·PR Newswire
Finance · Crypto
SINGAPORE, Oct 9, 2026 - Fullerton Fund Management (“Fullerton”) and SGX Group, in partnership with Moomoo Singapore as Supporting Partner, launched the second edition of the Fullerton / SGX Value-Up Singapore Equities Challenge(1) (“The Challenge”) to the public for the first time, inviting Singaporeans and Permanent Residents aged 18 and above to test their investing skills on Singapore-listed small and mid-cap companies over eight weeks, with cash prizes for the top performers.
The inaugural Challenge in 2025 was open to students only. This year’s edition adds an Open Category for the public while retaining the Student Category. Participants in both categories will research and manage virtual portfolios of eligible Singapore-listed securities, with a focus on Singapore’s small- and mid-cap (“SMID”) segment. The trading simulation does not involve real capital.
The Challenge comes as interest in Singapore’s SMID segment grows. As of 30 June 2026, institutional net buying in SMID stocks had tripled year on year to S$606 million, while daily trading value rose 155% to S$310 million, its highest level since FY2014(2). The Challenge gives participants a structured and practical way to learn more about companies beyond the Straits Times Index.
Open Category
Open to Singapore Citizens and Permanent Residents aged 18 and above, the Open Category will run from 7 December 2026 to 29 January 2027 over an eight-week online trading period. Participants compete individually, constructing and managing portfolios from an eligible list of Singapore-listed securities. They will be ranked in real time on a leaderboard based on total portfolio return, with cash prizes of S$3,000, S$2,000 and S$1,000 for the top three participants.
Student Category
The Student Category returns for its second year and is open to Singapore Citizens and Permanent Residents aged 18 and above who are enrolled full-time in polytechnics or universities. Participants compete in teams of four in the same eight-week simulation, using eligible Singapore-listed securities focused primarily on the SMID segment.
The top six teams from the qualifying round will advance to an in-person stock-pitch final, where they will present their research and investment thesis to a judging panel. The top three teams will receive cash prizes of S$10,000, S$5,000 and S$3,000. The category is designed to connect classroom learning with practical exposure to investing, industry practitioners and potential 8-month internship opportunities, through the Fullerton Singapore Value-Up Internship Programme.
Building disciplined investment habits
The Challenge is designed to encourage disciplined portfolio construction rather than concentrated bets. Participants must establish positions within the first five trading days. From 14 December 2026, portfolios must maintain at least 80% exposure to eligible securities at the end of each trading day, with cash holdings capped at 20%. When initiating or adding to a position, exposure to any individual eligible security must not exceed 10% of the portfolio’s total value. Each portfolio may hold no more than 30 eligible securities; leverage, margin and derivatives are not permitted.
Through the Challenge, participants will be able to:
Gain first-hand experience in researching and evaluating Singapore-listed companies.
Develop practical habits around portfolio construction, risk management and investment decision-making.
Build a stronger understanding of opportunities available within Singapore’s equities market beyond the benchmark index.
Ken Goh, Chief Investment Officer, Fullerton Fund Management, said: “Over the past year, we have seen growing interest in Singapore equities, reflecting broader recognition of the depth and diversity of our domestic market. The objective of the Fullerton/SGX Value-Up Singapore Equities Challenge is to motivate participants to identify and capture rising shareholder value, by encouraging young investors and members of the public to research companies, assess their potential and construct portfolios with greater discipline. The Challenge also supports our broader commitment to talent development. Participants from the inaugural Challenge have since joined Fullerton as interns, demonstrating how practical exposure can help inspire and nurture the next generation of investment professionals. Through this Challenge, we hope to contribute to a more informed and engaged Singapore equities market, with a broader base of investors participating in its long-term development.”
Ng Yao Loong, Head of Global Financial Markets, SGX Group, said: “In every market, there is a difference between what is well known and what is well understood. The Fullerton/SGX Value-Up Singapore Equities Challenge encourages participants to close that gap by researching the SMID segment, testing their assumptions and forming their own investment perspectives. By opening the Challenge to the public, we hope more people will discover the breadth of the Singapore stock market and deepen their understanding of the businesses behind it.”
Jeyson Ng, CEO, Moomoo Singapore said: “We are pleased to support Fullerton and SGX, both of whom are Moomoo’s long-term strategic partners in the Singapore ecosystem, in making investing education more accessible to students and the wider public. Through practical learning resources on Singapore equities, company research and portfolio construction within the Moomoo app, we hope to help participants build the confidence and foundational skills to better understand the market. The Challenge also provides a meaningful platform for us to engage aspiring talent and nurture the next generation of finance and technology professionals.”
Registration for both categories is open until 30 November 2026. A participant may register for either the Student Category or the Open Category (provided that it meets the relevant eligibility requirements), but not both. Interested parties may sign up at https://value-up.investsg.asia/
(1) Jointly developed by SGX Group and AlphaInvest
(2) SGX Group Research
About Fullerton Fund Management
Fullerton Fund Management Company Ltd (“Fullerton”) is an active investment specialist, focused on optimising investment outcomes and enhancing investor experience.
We help clients, including government entities, sovereign wealth funds, pension plans, insurance companies, private wealth and retail, from the region and beyond, to achieve their investment objectives through our suite of solutions. Our expertise encompasses equities, fixed income, multi-asset, alternatives and treasury management, across public and private markets.
As an active manager, we place strong emphasis on performance, risk management and investment insights. Incorporated in 2003, Fullerton is headquartered in Singapore, and has associated offices in Shanghai, Brunei and Jakarta. Fullerton is part of a multi-asset management group, Seviora, a holding company established by Temasek. Income Insurance, one of Singapore’s leading insurers, is a minority shareholder of Fullerton.
For more information, please visit www.fullertonfund.com
About SGX Group (Singapore Exchange)
SGX Group is one of the world’s most trusted international marketplaces, known for its stability and openness. Anchored in Singapore, we enable price discovery, capital formation and risk management across asset classes, supported by resilient infrastructure and robust clearing. We convene issuers, investors and intermediaries to create and grow markets that stand the test of time. Find out more at www.sgxgroup.com.
About Moomoo Singapore
Moomoo Singapore is a holistic wealth-tech platform building an intelligent investing ecosystem across its digital platform, physical experience stores and investor education community. Through the moomoo app, it provides everyday investors and professional clients with access to global markets, diverse investment products, advanced trading tools and AI-powered insights.
Since launching in March 2021, Moomoo Singapore has evolved beyond an investing platform into a popular financial literacy resource and full-spectrum wealth platform, supporting investors from their first trade to managing sophisticated portfolios. It surpassed two million users in Singapore in June 2026, spanning retail investors to private wealth and institutional clients.
Moomoo Financial Singapore Pte. Ltd. is a subsidiary of Nasdaq-listed Futu Holdings Limited (Nasdaq: FUTU). The firm is regulated by the Monetary Authority of Singapore and holds a Capital Markets Services Licence (CMS101000) and Major Payment Institution Licence (PS20200617). It also has exempt financial adviser status and is authorised to provide Digital Payment Token services. Moomoo Trustee (Singapore) Pte. Ltd. is a licensed trust company, while Moomoo Singapore is a DP Clearing Member, SGX-ST Trading Member, and SGX-DT Trading and Clearing Member of Singapore Exchange.
Find out more at https://www.moomoo.com/sg
For media queries, please contact:
Rishika Tiwariemail: rishika@financialpr.com.sg
Oct 9 · 06:50·ACN Newswire
AI · SaaS
Hong Kong, Oct 9, 2026 - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies.
The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. At Everest, they will drive clinical development of the Company’s mRNA programs and expand Everest’s presence in the United States, in line with the Company’s global mRNA R&D strategy, while working closely with the China R&D team.
The two scientists previously held leadership roles at Moderna, where they contributed to its mRNA cancer vaccine programs, including mRNA-4157/V940. Their experience spanning early-stage research through clinical development will support the advancement of Everest's proprietary mRNA platform and global clinical development programs. In August 2026, Moderna and Merck announced that mRNA-4157/V940 in combination with Keytruda met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 study. The results represent the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy.
“We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest Medicines as we continue to strengthen our global mRNA R&D capabilities,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy.”
Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept. Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics, which was later acquired by BioNTech, and Sanofi Oncology. Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020) and Cancer Cell (2022), and co-authored publications on Moderna’s intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024) and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026).
Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies. Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), which reported positive results from the Phase 3 INTerpath-001 study in August 2026, becoming the first personalized neoantigen therapy and mRNA cancer therapy to achieve success in a Phase 3 clinical study. Dr. Coder also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106. He contributed to nine IND submissions as a co-inventor, research lead, or core contributor, and co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024). Prior to joining Moderna, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines.
Leveraging its proprietary AI+mRNA platform, Everest Medicines is advancing multiple mRNA oncology therapeutic vaccine and in vivo CAR-T programs for oncology and autoimmune diseases. EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, EVM16 plans to initiate an investigator-initiated trial (IIT) Phase 1b study in Q4 2026 and launch new indication expansion cohorts for efficacy exploration. The company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027. EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China’s National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.EVM18, an in vivo CAR-T therapy, has initiated an IIT study in autoimmune diseases, with global IND filing underway. EVM15, an off-the-shelf immunomodulatory (IM) cancer vaccine, achieved clinical proof of concept in preclinical studies in 2025, with a clinical candidate subsequently selected. The Company plans to advance preparations for the Investigational New Drug (IND) application for EVM15 in 2026.
Oct 9 · 05:56·ACN Newswire
SaaS
Under the Patronage of His Excellency Prabowo Subianto, President of the Republic of Indonesia JAKARTA, Indonesia, Oct. 9, 2026 -- A new global platform for investment, capital formation and economic partnership will launch 3-4 December in Bali, Indonesia. The New Asia Forum...
Oct 9 · 05:42·PR Newswire
Finance · SaaS
Quantisimo Corp., the Pure-Play Sovereign Quantum Vertical Platform “Root to Qubit” Formed by WISeQey and SEALSQ, Signs Definitive Business Combination Agreement with GigCapital8 Corp. to Become a Nasdaq-Listed Public Company
Oct 9 · 05:00·GlobeNewswire
Finance · AI
Hong Kong, Oct 9, 2026 - As AI Drug Development Approaches Commercialization, MindRank Marks a Key Business Milestone
How much value can AI create in the discovery and development of new medicines' For investors following the sector, the answer lies in tangible progress in drug development and business execution. A platform’s ability to consistently generate drug candidates, advance lead assets through clinical development and secure recognition from industry partners provides an important basis for assessing an AI drug developer’s growth potential.
The recently announced commercialization partnership by MindRank AI Ltd. (MindRank, hereinafter “MindRank”) offers a new window into this question.
On September 28, 2026, MindRank announced an exclusive commercialization partnership with 3SBio (01530.HK) subsidiaries Sunshine Mandi and Wansheng Pharmaceutical for MDR-001, its internally developed, AI-designed oral small-molecule GLP-1 receptor agonist. Covering mainland China, Hong Kong and Macau, the agreement carries a potential total transaction value of up to RMB1.75 billion, alongside a substantial share of sales revenue. MDR-001 is currently undergoing a pivotal Phase III clinical trial in China in adults with obesity or overweight.
For MindRank, a clinical-stage AI-native drug discovery and development technology company, the partnership further connects drug development with commercialization planning. It lays the groundwork for marketing its lead asset following potential approval and establishes a clearer pathway for translating AI-driven research into commercial value. As its lead asset advances through pivotal clinical development, MindRank has begun preparing for post-approval marketing and channel coverage, extending the product’s development pathway into commercialization.
Under the agreement, Sunshine Mandi and Wansheng Pharmaceutical will provide exclusive, comprehensive services and distribution across all channels following MDR-001’s launch. MindRank will retain all rights, title and interests in the product’s intellectual property and remain responsible for clinical development, regulatory submissions, manufacturing and supply. The transaction includes up to RMB150 million in payments for collaboration rights, up to RMB1.6 billion in royalty payments upon the fulfillment of agreed conditions, and a substantial share of sales revenue.
From a business-model perspective, the agreement establishes a clear division of responsibilities. MindRank will continue investing in research and product development, while its partners will provide exclusive, comprehensive services and distribution across all channels within the agreed territories following regulatory approval and launch. In an industry that requires sustained investment, this collaboration could help MindRank retain its core asset rights while drawing on its partners’ commercial capabilities to support launch preparations and focus its own resources on strengthening its core capabilities.
The partners’ willingness to make commercialization arrangements for an investigational drug also provides a new reference point for assessing its potential industry value. Clinical data address whether a product merits further development, while commercial partnerships indicate whether industry participants are willing to take part in its subsequent development. Together, these elements make MindRank’s growth story more tangible.
A Lead Asset in Phase III Provides a Clearer Basis for Assessing AI-Driven R&D Capabilities
The core asset underpinning the partnership is MDR-001, which continues to advance through development.
In February 2026, MindRank announced that the first participant had been dosed in MOBILE, its Phase III clinical trial of MDR-001. According to the company, the multicenter, randomized, double-blind, placebo-controlled study plans to enroll approximately 750 participants across around 50 clinical centers in China to further evaluate the product’s long-term efficacy and safety.
This means the evidence available to assess MindRank’s AI-driven R&D capabilities now extends to larger-scale, late-stage clinical research. For investors, the lead asset’s entry into Phase III sharpens the focus on several key questions: whether long-term efficacy can be further validated, whether safety and tolerability findings can be sustained, and whether the product can establish clinically meaningful competitive advantages.
Previously disclosed Phase IIb findings supported further development. In the study, which enrolled 317 adults with obesity or overweight, participants in the MDR-001 dose groups achieved mean reductions in body weight from baseline of 8.2% to 10.3% after 24 weeks, compared with 2.5% in the placebo group. The rate of treatment discontinuation due to treatment-emergent adverse events was 0.8%. Common adverse events were primarily gastrointestinal and mostly mild to moderate. These findings remain subject to further validation in subsequent studies.
For weight-management medicines, product value depends on a combination of weight-loss efficacy, long-term safety, tolerability and ease of use. Compared with the injectable peptide-based GLP-1 medicines that currently dominate the market, MDR-001’s oral small-molecule formulation can significantly improve medication adherence, while its large-scale manufacturing costs are substantially lower than those of peptide-based medicines, offering considerable market potential and commercial value. These attributes provide a promising direction for its future product positioning, although translating them into a competitive advantage will require continued accumulation of clinical evidence.
Beyond progress in product development, R&D efficiency is another important lens through which to assess MindRank.
According to the company, MDR-001 progressed from project initiation to preclinical candidate (PCC) nomination in just eight months, during which approximately 80 small molecules were synthesized. Its investigational new drug (IND) application was cleared in the United States within 19 months of project initiation and MDR-001 advanced to Phase III in China in approximately 4.5 years. In its July 2026 financing announcement, the company further disclosed that cumulative direct R&D investment in the program, from initiation through the start of Phase III in China, totaled approximately US$23 million.
These timelines and investment figures provide a more concrete basis for understanding how MindRank organizes drug discovery and development. For drug developers, development timelines and funding requirements directly affect how many programs they can advance, how long they can sustain development and how they allocate resources to subsequent work. AI’s commercial significance must also be assessed within these real-world R&D constraints.
As a flagship application of MindRank’s AI-driven drug discovery and development system, MDR-001 offers a traceable development pathway: from molecular design to clinical research and, subsequently, commercialization partnerships. The platform’s capabilities are beginning to be tested through tangible business outcomes. This provides capital markets with a more useful basis for understanding the company’s technology value than descriptions of algorithms or model parameters alone.
Beyond the Lead Asset, Long-Term Growth Depends on Sustained Platform Output
MDR-001 is the central focus of MindRank’s business progress at this stage, while the company’s long-term growth potential also depends on its ability to continue developing new drug assets.
According to the MindRank, its end-to-end AI drug development engine, MAP (Molecule Arts Platform), integrates biology, chemistry, computation, experimental validation and clinical learning into a unified drug discovery and development system. In July 2026, the company announced that it had completed a cumulative US$52 million Series B financing in stages, with proceeds earmarked for further platform development and the advancement of its clinical and preclinical pipeline. In September 2026, the company formally launched Intera (Intelligence Era), its life-sciences foundation model system, and released a technical report on InteraFold-Chem, the first model in the InteraFold series.
From an operating perspective, platform development and pipeline advancement have the potential to reinforce each other. R&D programs bring real-world problems and experimental feedback to the platform, while platform iterations support the discovery and optimization of subsequent programs. Ultimately, the platform’s value must be reflected in sustained output: its ability to advance more molecules with development potential across different targets and disease areas, gradually building a business supported by multiple assets.
MindRank has already expanded beyond metabolic diseases. In March 2025, the company disclosed that MRANK-106, an oral dual inhibitor of WEE1 and YES1, had received IND approval in the U.S. in oncology. This development provides another case through which to assess the applicability of its AI platform across different R&D areas, although the product’s potential remains subject to subsequent clinical validation.
In earlier-stage research, the company disclosed in April 2026 that a collaborative study on drug discovery for Alzheimer’s disease, conducted by MindRank, the University of Macau and Imperial College London, had been published in Nature Biomedical Engineering. The work combined AI screening with experimental validation to identify small molecules meriting further investigation, demonstrating the company’s research capabilities and exploration at the forefront of drug discovery for complex diseases.
These programs are at different stages, and their contributions to the company’s value need to be assessed separately. MDR-001 remains the main focus of current clinical development and commercialization preparations, while other pipeline programs and research support the platform’s broader applicability and long-term project portfolio. As more programs deliver verifiable progress, outside observers will be better positioned to assess whether the company can consistently replicate its R&D capabilities.
Viewed through this lens, the recent commercialization partnership offers an opportunity to reassess MindRank. Its lead asset has entered pivotal clinical development, partners are participating in commercialization preparations at an early stage, financing supports continued R&D, and its presence across multiple areas preserves opportunities for future growth. These interconnected developments make the company’s development trajectory easier for capital markets to understand.
MDR-001 remains in clinical development and has not yet received marketing approval. Its future value realization depends on clinical results, regulatory approval and commercial execution. Nevertheless, the business progress achieved to date provides a more concrete basis for assessing MindRank. For investors following opportunities at the intersection of AI and innovative medicines, the central question worth tracking is whether the company can progressively translate its established R&D capabilities into more verifiable drug assets and commercial outcomes.
Oct 9 · 03:34·ACN Newswire
AI · SaaS
Bellingham, Wa. Thursday Oct 8, 2026 @ 6:30 PM Pacific —
Nationally touring comedian Myq Kaplan will headline a special one-night performance at Bar Two Eleven in downtown Bellingham on Friday, Oct. 23, bringing one of stand-up comedy's sharpest comedic voices to Northwest Washington.
Kaplan has appeared on The Tonight Show Starring Jimmy Fallon, Conan, The Late Show with David Letterman, The Late Late Show, and Comedy Central Presents. His insightful humor and signature wordplay have garnered a global fanbase.
"I love doing comedy anywhere, and Bellingham is one of those anywheres!" said Kaplan.
Kaplan is also well known within the vegan community. His first comedy album, Vegan Mind Meld, introduced audiences to comedy inspired by his vegan lifestyle, a theme that still appears throughout his stand-up today.
"As a vegan, Bellingham is one of my favorite hams," Kaplan joked.
The performance is presented by Guffawingham, a local comedy series created by comedian and producer Tim Riney. The series brings nationally touring comedians together with regional performers, giving Bellingham audiences more opportunities to experience live stand-up close to home.
The evening also features Richard Bowen, a Seattle comedian known for his rapid-fire one-liners and sharp observations. Bowen earned national recognition after being named Laffy Taffy's "Chief Laugh Officer."
Rounding out the lineup is Brett Emerson, a longtime Bellingham comedian whose quick wit and fearless sense of humor have made him a familiar face on stages throughout the region.
"I love performing in the Pacific Northwest, because I'm a pacifist, a northerner, and a big fan of Mae West," Kaplan said.
The performance is expected to draw comedy fans from throughout Northwest Washington and nearby British Columbia for a rare opportunity to see a nationally touring headliner in an intimate downtown venue.
Event Details
Date: Friday, Oct. 23, 2026
Venue: Bar Two Eleven
211 E. Chestnut Street
Bellingham, WA
Doors Open: 7:00 p.m.
Show Starts: 8:00 p.m.
Tickets: https://www.tickettailor.com/events/guffawingham/2444106
About Myq Kaplan
Myq Kaplan is a nationally touring comedian, writer, actor, and podcast host. His television appearances include The Tonight Show Starring Jimmy Fallon, Conan, The Late Show with David Letterman, The Late Late Show, and Comedy Central Presents. He has released multiple acclaimed comedy specials and albums and continues to perform at clubs, theaters, and festivals throughout North America.
Oct 9 · 01:30·Newsworthy.ai
AI · SaaS
67MW expansion brings Bitdeer AI’s secured AI Cloud data center capacity to approximately 273.5MW, or approximately 78% of its target of up to 350MW to be delivered by the first quarter of 2028
67MW expansion brings Bitdeer AI’s secured AI Cloud data center capacity to approximately 273.5MW, or approximately 78% of its target of up to 350MW to be delivered by the first quarter of 2028
Oct 8 · 22:27·GlobeNewswire
Finance · SaaS
TNCDP Joins KoreInside Infrastructure to Advance Digital Preferred Stock Through Its Capital Markets Platform
Oct 8 · 20:56·GlobeNewswire